Head-to-head · WeighScore
LillyDirect Foundayo vs No BS RX
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 67.2/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.
Before you choose
LillyDirect Foundayo does not publish a semaglutide price, so its LillyDirect Foundayo review sets out what it does disclose, while the No BS RX review explains the conditions attached to No BS RX's figure. The semaglutide cost page compares published rates across the field. Ask LillyDirect Foundayo for a written total before treating either one as the cheaper choice.
If neither one fits, LillyDirect Foundayo vs Ro and Longevixx vs No BS RX compare each of them with another graded program, and the list of alternatives to LillyDirect Foundayo ranks the programs closest to LillyDirect Foundayo on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the HealthRX review covers one graded close to these two, at 77.5/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | LillyDirect Foundayo | No BS RX |
|---|---|---|
| WeighScore | 67.2/100 | 82.8/100 |
| Grade | C | B− |
| Site position | #180 | #23 |
| Semaglutide | Not disclosed | $149/mo advertised for standard compounded injection; low-dose priced separately |
| Tirzepatide | Not disclosed | $225/mo advertised for standard compounded injection; low-dose priced separately |
| Coverage | Confirm pharmacy delivery and offer eligibility | Confirm program availability for your state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Strengths
- Published cash and commercial savings terms
- LillyDirect is one of several listed pharmacy routes
What to consider
- A prescription is required and care costs are separate
- Price varies by strength and offer eligibility
- Some continuing discounts have refill-purchase timing requirements
Strengths
- Displays monthly and prepaid amounts by program
- Advertises consultation, medication, shipping and messaging in the compounded plans
- Lists branded Ozempic and Zepbound separately
What to consider
- The $115 headline applies to low-dose programs
- Plans renew automatically at the then-current rate
- Cancellation generally stops future billing without refunding the current period
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.